Advertisement

Picture Berlin Partner HealthCapital RegMed Forum 2018 October 600x60px
Document › Details

Forma Therapeutics. (3/13/17). "Press Release: Forma Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim". Watertown, MA.

Organisations Organisation Forma Therapeutics Inc.
  Group Forma Therapeutics (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product cancer drug
  Product 2 drug development
Index term Index term Boehringer–Forma Therapeutics: cancer drugs, 201201– collab r+d $65m upfront + funding + $750m milestones small-molecule cancer drugs
     


FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, today announced the achievement of a clinical development milestone in their alliance with Boehringer Ingelheim (BI). The partnership focuses on the discovery and development of novel drug candidates against protein-protein interactions for the treatment of cancer. Financial milestones payable to FORMA for this achievement have not been disclosed.

“FORMA’s discovery and early clinical development successes, across our wholly-owned pipeline as well as programs in collaboration with pharmaceutical partners, accentuates the value of a unique compound collection and productivity of talented teams across collaborative networks” said John Hohneker, M.D., EVP and Head of Research and Development at FORMA. “We are pleased to see tractable progress of protein-protein modulators and to have contributed to BI’s clinical candidate pipeline, enabled by the collective grit of R&D teams, boldly and courageously taking on such challenging programs.”

“We are pleased to see tractable progress of protein-protein modulators and to have contributed to BI’s clinical candidate pipeline, enabled by the collective grit of R&D teams, boldly and courageously taking on such challenging programs.”


About FORMA

FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates that will ultimately provide profound patient benefit.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com

Join our conversation on Twitter @FORMAInc.


Media Contact

For FORMA Therapeutics
Kari Watson +1 781-235-3060
kwatson@macbiocom.com
MacDougall Biomedical Communications

   
Record changed: 2017-04-19

Advertisement

Picture Lipotype Lipidomics Drug Biomarker Discovery iito 600x60px

More documents for Forma Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px




» top